Report Library
All Reports
2015 Chronic Lymphocytic Leukemia (CLL) KOL Interview
January 28, 2015
Following our live coverage of ASH, we interviewed a KOL who specializes in treating lymphoid malignancies to provide further insight
on current and future paradigms for the treatment of CLL and NHLs.
Key Highlights
For our disclosures, please read the BioMedTracker Research Standards. BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
Key Highlights
- High response rates for checkpoint inhibitors in Hodgkin's Lymphoma may suggest long duration of response, but follow-up times are insufficient to draw conclusions.
- CAR-T cells (JUNO, NVS, KITE) have potential in DLBCL and for late-line treatment in some CLL patients, but current data do not strongly favor any particular CAR-T program.
- Venetoclax (ABT-199, ABBV) is highly effective in CLL, including relapsed/refractory and del17p patients and appears to be fairly well tolerated.
- Overall survival benefit for obinutuzumab (Gazyva, Roche) vs. rituximab, either with chlorambucil or bendamustine for CLL, or with CHOP for DLBCL, could compel improved obinutuzumab adoption.
- Tests for MRD negativity in CLL currently have limited utility outside of clinical trials since no evidence to guide treatment based on MRD status currently exists.
For our disclosures, please read the BioMedTracker Research Standards. BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
| Indications Covered: | Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL |
Additional Resources: